Irving Investors

Navan is a company that specializes in corporate travel management, expense management, and corporate card solutions aimed at automating manual processes and enhancing spend visibility. By leveraging advanced technologies such as artificial intelligence and cloud computing, Navan offers a modern platform that prioritizes traveler safety while controlling costs. The company focuses on providing seamless travel booking and itinerary management, ensuring that businesses can manage their travel needs effectively and efficiently. Through its innovative approach, Navan aims to transform the traditional travel and expense management landscape by delivering high-quality service and actionable real-time data to its clients.

Caris Life Sciences, Inc. is a biotechnology company specializing in molecular profiling and advanced diagnostic technologies aimed at improving cancer patient outcomes. Founded in 1987 and headquartered in Irving, Texas, with additional offices in Phoenix and Basel, the company develops solutions that leverage artificial intelligence and machine learning to analyze the molecular complexity of diseases. Caris offers a range of services, including anatomic pathology, drug development, and molecular analyses of patient samples, which include genomic, transcriptomic, and proteomic profiling. Their Comprehensive Oncology Data Explorer serves as a clinico-genomic data platform. By providing insights into DNA, RNA, and protein profiles, Caris enables healthcare professionals to make more precise and personalized treatment decisions for oncology and other complex diseases. The company operates through distributors across the United States, Europe, Australia, and globally, and has established strategic collaborations to enhance its offerings.

CoreWeave operates a cloud infrastructure platform that delivers computing power primarily for blockchain and artificial intelligence/machine learning projects. The company’s specialized GPU cloud system enhances workflows and allows clients to efficiently scale their operations according to the complexity of their models. This flexibility enables users to access tailored compute resources, facilitating innovation and adaptation to rapidly changing computational needs. CoreWeave's platform is designed to support a variety of initiatives, making it a valuable resource for enterprises seeking to optimize their technological capabilities.

OpenAI is an artificial intelligence research and deployment company focused on developing machine learning technologies that aim to create safe artificial general intelligence for the benefit of all users. The company engages in projects related to autonomous learning and task performance across various industries, including technology, healthcare, and education. OpenAI's platform directs artificial intelligence applications and is involved in policy work, education, and outreach, enabling clients to enhance their skills and knowledge while leveraging autonomous systems that can surpass human performance in economically valuable tasks.

Turo Inc. is an online car rental marketplace that connects local car owners with travelers seeking to rent vehicles. Founded in 2009 and based in San Francisco, California, Turo allows users to list their cars for rent, offering options for local pickup, city delivery, and airport delivery. The platform provides a wide selection of vehicles at competitive prices, enabling car owners to earn income while providing convenient access to cars for renters. Turo facilitates a peer-to-peer car-sharing model, creating a vibrant community of trusted hosts and enhancing the travel experience for users. The company was formerly known as RelayRides, Inc. before rebranding in November 2015.

Attentive is a leading provider of conversational commerce solutions, specializing in a personalized mobile messaging platform that enhances business-to-consumer communication. The company enables brands and organizations to engage with customers using behavioral data, allowing for the automatic delivery of tailored mobile messages throughout the customer lifecycle. This includes functionalities such as product recommendations, limited-time sales, payment processing, and real-time customer service. By focusing on SMS as a primary channel, Attentive helps e-commerce and retail businesses forge stronger connections with mobile shoppers, transforming the way they interact and communicate with their audiences.

OneTrust, LLC is a technology company that specializes in privacy management and compliance solutions. Founded in 2016 and headquartered in Atlanta, Georgia, the company offers a comprehensive platform that automates various aspects of privacy program management, including privacy impact assessments, data inventory mapping, and risk remediation actions. OneTrust’s solutions facilitate compliance with global regulations by providing tools for vendor risk management, incident reporting, and website compliance, as well as managing data subject rights and consent. The platform serves a diverse clientele ranging from multinational corporations to small and medium enterprises, allowing them to collaborate effectively on privacy risks associated with customer, employee, and vendor data. OneTrust also provides training and certification programs, ensuring that organizations can maintain continuous compliance through ongoing audits and assessments. With additional offices worldwide, OneTrust is positioned to support businesses in navigating the complexities of privacy regulations across various sectors and jurisdictions.

Databricks Inc. is a technology company that provides a unified data analytics cloud platform designed to facilitate data engineering and collaborative data science. The company offers a comprehensive suite of tools, including a just-in-time data platform that simplifies data integration, real-time experimentation, and deployment of production applications for developers and data scientists. Key products include Databricks Delta, which combines the capabilities of data warehouses with low-latency streaming, MLflow for managing the machine learning lifecycle, and Delta Lake for handling batch and streaming data. Databricks serves a diverse range of industries, including advertising, healthcare, manufacturing, and telecommunications, and has established strategic partnerships with various organizations to enhance its offerings. Founded in 2013, Databricks is headquartered in San Francisco, California, with additional offices in London, Amsterdam, and Bengaluru.

Celonis is a company that specializes in execution management, focusing on optimizing and analyzing business processes across various industries, including production, human resources, and logistics. Its core product, the Celonis Execution Management System (EMS), utilizes advanced process mining technology to enhance productivity and streamline operations. The EMS provides a comprehensive suite of tools and applications, including Celonis Studio, designed for business executives and users to effectively manage execution across analytics, strategy, planning, and automation. By offering unique software solutions, Celonis enables organizations to improve process transparency and efficiency, ultimately unlocking their full execution capacity.

Icertis is a cloud-based enterprise contract management platform that addresses complex contract management challenges through an intuitive interface. Founded in 2009 and headquartered in Bellevue, Washington, Icertis utilizes artificial intelligence to analyze and structure various types of contracts, helping organizations streamline their processes. The platform enhances contract velocity, ensures compliance with regulatory and policy requirements, and optimizes commercial relationships by maximizing revenue and minimizing costs. By providing detailed risk reports and automating the management of obligations, Icertis enables clients to improve governance, mitigate risks, and boost overall productivity.

Snyk Ltd. is a software as a service company that specializes in application security, enabling developers to identify and remediate vulnerabilities within their code and associated components. Founded in 2015 and headquartered in London, Snyk offers a suite of tools designed for modern application development, including Snyk Code for static application security testing, container vulnerability management, and infrastructure as code security solutions. The platform seamlessly integrates into developers' workflows, allowing security teams to collaborate effectively with development teams. Snyk's services encompass monitoring application dependencies for vulnerabilities, ensuring licensing compliance, and providing detailed reports and issue tracking. With a client base of 1,200 organizations, including prominent companies like Google and Salesforce, Snyk empowers developers to build secure applications while enhancing overall security posture and productivity. The company also maintains a strategic partnership with Rapid7, further extending its capabilities in the security landscape.

Chainalysis Inc. is a blockchain analysis company that specializes in anti-money laundering software tailored for cryptocurrency businesses. Founded in 2014 and headquartered in New York, with additional offices in Copenhagen, Tokyo, and Singapore, the company offers a suite of products designed to enhance compliance and security in the cryptocurrency space. Key offerings include REACTOR, an interactive investigation tool that identifies offenders and visualizes data; a transaction-based risk scoring API that assesses the source and destination of funds; and various activity monitoring reports and due diligence tools that help financial institutions understand and mitigate risks associated with cryptocurrency transactions. Chainalysis serves a wide range of clients, including government agencies, banks, exchanges, and other financial institutions, providing them with the necessary tools to navigate the complexities of blockchain technology and ensure compliance with regulatory standards.

Klaviyo, Inc. is a technology company headquartered in Boston, Massachusetts, with an additional office in London, United Kingdom. Founded in 2012, Klaviyo specializes in providing an email marketing software platform designed to help businesses grow through effective marketing automation. Its features include a library of best practice emails, segmentation tools, analytics, customer profiles, and support for various campaigns such as abandoned cart reminders and personalized follow-ups. Klaviyo's platform integrates with customer data sources to deliver tailored messaging across email, SMS, and push notifications, enabling businesses to engage with customers at the right time. The company utilizes machine learning and artificial intelligence to enhance its services and measures performance to optimize marketing efforts. Klaviyo generates revenue through subscription sales for its software-as-a-service platform, focusing primarily on the eCommerce sector.

Leap Services, Inc. operates a retail-as-a-service platform designed to enhance the retail sector. Founded in 2018 and headquartered in Chicago, Illinois, Leap enables brands to establish retail stores in optimal locations under favorable terms. The platform encompasses all facets of store development and operations, including physical space management, staffing, and technological infrastructure. This comprehensive approach allows consumer brands to accelerate growth and enhance customer engagement through a seamless omnichannel experience. Leap operates retail stores in major cities such as New York City, San Francisco, Chicago, and Miami, positioning itself as a vital partner for high-growth brands seeking to thrive in the evolving retail landscape.

Metagenomi, Inc. is a biotechnology company focused on developing gene editing systems aimed at treating genetic diseases. Founded in 2016 and based in Emeryville, California, Metagenomi utilizes metagenomics and machine learning to uncover novel genome editing technologies derived from previously uncharacterized organisms. The company's innovative discovery platform enables the creation of highly efficient and specific gene editing tools, including programmable nucleases, base editors, and advanced integration systems such as prime editing and CRISPR-associated transposases. By harnessing these naturally evolved systems, Metagenomi seeks to address a wide range of genetic mutations that traditional genome engineering approaches have struggled to target, with the ultimate goal of providing transformative therapies for patients globally.

Checkr, Inc. is a technology-driven company focused on the background check industry, offering a comprehensive range of screening services, including criminal record checks, driving checks, and identity verification. Founded in 2014 and headquartered in San Francisco, California, Checkr utilizes advanced technology and data sources to deliver faster and more efficient background checks compared to traditional providers. The company emphasizes fairness and transparency in hiring, enabling businesses across various sectors, including financial services, healthcare, and staffing, to enhance their hiring processes. Checkr also provides compliance services and security solutions, ensuring a secure and streamlined experience for both employers and candidates. With its innovative platform, Checkr aims to improve the overall applicant experience while supporting companies in navigating the complexities of today's workforce dynamics.

Arctic Wolf Networks, Inc. is a cybersecurity company that provides security operations center-as-a-service to businesses, enabling them to manage and mitigate cyber risks effectively. The company offers a range of services, including cloud infrastructure monitoring, software-as-a-service application monitoring, vulnerability assessments, and account takeover risk detection. It also develops the Arctic Wolf Agent, a software tool that collects actionable intelligence from IT environments. Serving industries such as financial services, healthcare, and legal, Arctic Wolf employs a concierge security model, where its engineers work closely with clients to deliver tailored threat detection, response, and ongoing risk management. Founded in 2012 and headquartered in Eden Prairie, Minnesota, the company also has offices in Provo, Utah, and Waterloo, Canada.

DNA Script is a pioneering company in the field of DNA synthesis, focused on enhancing life science and human health through innovative technology. The company has developed a unique enzymatic process that allows for the production of synthetic DNA using natural enzymes. This technology underpins their benchtop DNA printer, SYNTAX, which enables laboratories to synthesize their own oligonucleotides. By doing so, DNA Script provides researchers with greater control over their workflows, facilitating faster access to essential genomic materials for various applications in molecular biology and genomics. This capability accelerates experimentation and supports the development of new therapeutics, positioning DNA Script as a key player in the biotechnology sector.

Bombas is an apparel brand founded in 2013 in New York, specializing in the manufacture of high-quality athletic socks for men, women, teens, and girls. The company also offers a range of other products, including underwear and t-shirts. Through its online platform, Bombas provides customers with comfortable, soft, and durable apparel at affordable prices. In addition to its focus on quality, the brand is committed to social responsibility, donating one item for every item sold to those in need.

Shoreline Biosciences, Inc. is a biotechnology company based in La Jolla, California, founded in 2020. The company specializes in developing cell-based immunotherapies aimed at treating seriously ill patients. Shoreline utilizes a proprietary technology platform that focuses on induced pluripotent stem cell (iPSC) differentiation and the genetic programming of the IL-15/CISH pathway. This approach enhances the metabolic fitness and persistence of engineered natural killer (NK) cells, thereby improving their anti-cancer activity. In addition to NK cells, Shoreline is also advancing the development of iPSC-derived macrophages for oncology and disease-modifying therapies. The company's innovative solutions aim to provide healthcare professionals with effective and cost-efficient treatment options for patients facing serious health challenges.

InterVenn is a life science company focused on glycoproteomics, the study of glycosylated proteins that play a crucial role in protein function. The company's pioneering AI-powered platform aims to decode the glycoproteome, which contains vital information about human biology, thereby enhancing patient outcomes. InterVenn's technology facilitates the identification, quantification, and classification of glycoproteomic signals found in blood and tissue, enabling early detection and diagnosis of cancers, particularly ovarian cancer. This platform not only supports clinical applications such as disease screening and diagnostics but also offers valuable insights for pharmaceutical partners involved in research and development. Founded by notable scientists, including Nobel Laureate Dr. Carolyn Bertozzi, InterVenn is positioned to advance personalized, predictive, and preventative healthcare solutions.

Genomatica, Inc. is a biotechnology company based in San Diego, California, specializing in the development of manufacturing processes for intermediate and basic chemicals derived from renewable feedstocks. Founded in 1998, the company utilizes its proprietary biotechnology platform to create fermentation-based processes and to engineer microorganisms that facilitate the conversion of these feedstocks into essential chemicals. Genomatica has successfully commercialized processes for chemicals such as butanediol, which is used in biodegradable plastics and apparel, and butylene glycol, commonly found in cosmetics and personal care products. The company is also actively working on bio-nylon and has developed a pipeline targeting the production of 20 different chemicals. Recognized for its innovative technologies, Genomatica has received numerous accolades, including the Kirkpatrick Award for outstanding chemical engineering technology and the ICIS Innovation Award for its Brontide butylene glycol.

Cybereason Inc. is a cybersecurity company specializing in endpoint protection through its advanced platform that offers endpoint detection and response, next-generation antivirus, and anti-ransomware solutions. Founded in 2012 and headquartered in Boston, Massachusetts, with additional offices in London, Tel Aviv, and Tokyo, Cybereason's platform utilizes a custom-built in-memory graph to automate the detection of behavioral patterns across endpoints. This technology allows organizations to identify and respond to cyber threats effectively by revealing the full scope of an attack and enabling rapid response actions. The company's product offerings include solutions for behavioral data analysis, advanced attack prevention, and threat investigation, alongside managed monitoring and incident response services. Cybereason's focus is on providing enterprises with the tools needed to outmaneuver cyber adversaries.

BioTheryX, Inc. is a clinical-stage biopharmaceutical company based in Chappaqua, New York, focused on developing innovative therapies that restore protein homeostasis through targeted protein degradation. The company specializes in Protein Homeostatic Modulators and small molecule targeted protein degraders (TPDs), which utilize a unique mechanism involving molecular glues to regulate protein levels within the body. Their proprietary PRODEGY platform is built on a library of Cereblon binders, enabling the design of bifunctional and hybrid degraders aimed at treating various diseases, particularly cancer. BioTheryX's lead candidate, BTX-A51, is an oral small molecule and multi-kinase inhibitor targeting specific leukemic stem cells and oncogenic transcription factors. Established in 2007, BioTheryX aims to address significant unmet medical needs by leveraging its expertise in protein modulation and degradation.

LUMICKS specializes in advanced technologies for studying biology and cancer at the single-molecule and single-cell levels. The company focuses on bridging the gap between molecular structure and function, providing tools that enable real-time analysis of complex biological processes. Its flagship product, the C-Trap Optical Tweezers, combined with Fluorescence Microscopy, allows scientists to observe interactions at the single-molecule level. Additionally, the z-Movi Cell Avidity Analyzer measures and selects immune cells based on their real-time interactions with target cells. By facilitating live measurement and imaging, LUMICKS' instruments provide critical insights into the fundamental causes of diseases, including cancer, and hold potential for optimizing drug development.

Crossover Health, Inc. provides comprehensive workplace healthcare services tailored for employers and their employees. Founded in 2010, the company is headquartered in Aliso Viejo, California, with health centers located in various regions, including Silicon Valley. Crossover Health offers a wide range of services, including primary care, urgent care, chronic disease management, preventive care, health risk assessments, and health education. Additionally, it provides ancillary services such as physical therapy, chiropractic care, acupuncture, and care coordination, along with health analytics and remote care options. The company's focus is on creating a positive employee care experience that promotes a healthy and motivated workforce while delivering financial benefits to organizations.

Absci is a drug and target discovery company that leverages deep learning AI and synthetic biology to enhance the therapeutic potential of proteins. Its Integrated Drug Creation Platform streamlines the process of identifying novel drug targets, discovering optimal biotherapeutic candidates, and generating the necessary cell lines for manufacturing. By combining biologic drug discovery and cell line development into a single, efficient workflow, Absci collaborates with biotech and pharmaceutical innovators to develop next-generation protein-based drugs. These innovations include Bionic Proteins, which feature nonstandard amino acids, and other unique drug designs that may be unattainable through conventional methods. Absci's mission is to facilitate the development of improved medicines by effectively translating innovative ideas into viable drugs.

Egenesis Inc. is a biotechnology company focused on gene editing and genome engineering to create human transplantable organs, tissues, and cells. Established in 2015 and headquartered in Cambridge, Massachusetts, with an additional office in New York City, Egenesis aims to address the global organ shortage by developing solid organs and therapeutic cell transplantation solutions for various diseases. The company utilizes a gene editing platform that incorporates techniques such as single-cell cloning and somatic cell nuclear transfer, which are essential for creating human-compatible organ tissues and cells. Egenesis is particularly engaged in advancing programs related to kidney and islet cell transplantation, striving to provide alternative treatment options for patients with life-threatening conditions.

Model Medicines is a company focused on accelerating drug development through the integration of human expertise and artificial intelligence. Utilizing its ActivPred AI Drug Discovery Platform, Model Medicines applies machine learning to model chemistry and human biology, which facilitates the discovery of therapeutics that can be repositioned for treating complex diseases. The company has developed a robust pipeline of patent-pending therapeutics targeting various medical conditions, including oncology, infectious diseases, neurological disorders, and gastric disorders. By leveraging drug development data alongside advanced AI techniques, Model Medicines aims to expedite the clinical trial process, allowing new drugs to enter trials within a matter of months, thereby enhancing the efficiency and effectiveness of drug development for healthcare institutions.

NexImmune, Inc. is a clinical-stage biopharmaceutical company based in Gaithersburg, Maryland, specializing in the development of innovative immuno-therapeutics utilizing its proprietary Artificial Immune (AIM) technology. This technology is designed to enhance the immune system's ability to generate specific responses to targeted antigens, which is crucial for effective cancer treatment and other immune-mediated diseases. NexImmune's product offerings include AIM101, an injectable therapy for certain solid tumors, and AIM ACT, an adoptive cellular therapy aimed at treating specific hematological malignancies. The company is currently advancing two product candidates in human trials: NEXI-001 for acute myeloid leukemia and NEXI-002 for multiple myeloma. By focusing on improving the body's T cell responses, NexImmune aims to provide curative therapies for patients facing life-threatening conditions.

Imago BioSciences is a clinical-stage biotechnology company based in Redwood City, California, that specializes in developing innovative medicines for hematologic diseases. Founded in 2012, the company focuses on therapeutics that target genetic and epigenetic factors, specifically through the inhibition of lysine-specific demethylase 1 (LSD1), an enzyme crucial in blood cell production. Imago BioSciences aims to address significant medical challenges associated with conditions such as leukemia, myelodysplastic syndrome, and other bone marrow disorders. Its lead product candidate, Bomedemstat, is an orally available small molecule designed to treat certain myeloproliferative neoplasms, with the goal of altering disease progression and improving the quality and longevity of patients' lives.

Prometheus Laboratories Inc. is a specialty pharmaceutical and diagnostic company headquartered in San Diego, California, focused on developing and commercializing innovative products for individualized patient care, particularly in gastroenterology. Founded in 1995, the company offers a range of diagnostic tests, including Anser IFX and Anser ADA assays for monitoring drug and anti-drug antibody levels, as well as various tests for inflammatory bowel disease, celiac disease, and lactase intolerance. Their product lineup includes therapeutic monitoring tools, such as Anser UST for patients treated with Stelara, and diagnostic tests that utilize a proprietary algorithm to improve accuracy in patient assessments. Additionally, Prometheus Laboratories markets pharmaceutical products, including Entocort EC for Crohn's disease and Imuran for rheumatoid arthritis management. The company's commitment to innovation and precision healthcare enables physicians to optimize treatment strategies and enhance patient outcomes.

Nuvation Bio Inc. is a biopharmaceutical company dedicated to addressing unmet needs in oncology through the development of novel therapies for challenging cancers. Founded in 2018 and headquartered in New York, with an additional office in San Francisco, Nuvation Bio focuses on treating patients whose conditions have not responded to conventional treatments. The company's leading clinical-stage candidate, NUV-868, is a BD2-selective oral small molecule BET inhibitor that targets the BRD4 protein, which plays a crucial role in regulating tumor growth and differentiation. In addition to NUV-868, Nuvation Bio is advancing a proprietary small molecule Drug-Drug Conjugate platform aimed at enhancing therapeutic efficacy. The company’s comprehensive portfolio includes multiple drug development candidates designed to meet the specific needs of cancer patients.

Praxis Precision Medicines is a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system disorders marked by neuronal imbalance. Established in 2015 and headquartered in Cambridge, Massachusetts, the company leverages genetic insights to create innovative treatments for neurological and psychiatric conditions. Its leading product candidates include PRAX-114, an allosteric modulator targeting GABAA receptors, currently undergoing Phase IIa trials for major depressive disorder and perimenopausal depression, and PRAX-944, a selective inhibitor of T-type calcium channels in Phase IIa trials for essential tremor. Additionally, Praxis is advancing PRAX-562, a sodium current blocker in Phase I trials for severe pediatric epilepsy and adult cephalgia, along with PRAX-222, an antisense oligonucleotide aimed at treating patients with SCN2A epilepsy, and a program focused on KCNT1-related epilepsy. The company has established collaborations and licensing agreements with various organizations to enhance its research and development efforts.

Goldfinch Bio, Inc. is a clinical-stage biotechnology company based in Cambridge, Massachusetts, dedicated to discovering and developing precision therapies for patients with kidney diseases. The company focuses on conditions such as focal segmental glomerulosclerosis, diabetic nephropathy, and polycystic kidney disease. Key product candidates include GFB-887, a selective inhibitor of the TRPC5 channel, and GFB-024, a cannabinoid receptor 1 inverse agonist. Goldfinch Bio integrates advancements in kidney genetics and biology through its Kidney Genome Atlas, a genomic registry that aids in identifying new disease targets and biomarkers. Additionally, the company employs stem cell science to create human organoid models, which facilitate the validation of novel therapeutic targets. Goldfinch Bio has established a strategic collaboration with Gilead Sciences to further enhance its research and development efforts. Founded in 2016, Goldfinch Bio aims to transform the treatment landscape for progressive kidney disease.

Rubrik provides data management solutions, focusing on backup and recovery services for businesses of varying sizes. Their platform combines enterprise data management with web-scale IT, allowing companies to swiftly manage and protect their data across both private and public clouds. Rubrik's offerings aim to enhance cyber resilience, ensuring businesses can confidently embrace digital transformation while safeguarding their data.

Rebel Foods is a prominent operator of cloud kitchens that specializes in delivering food on demand through a variety of in-house brands. The company combines culinary expertise with advanced technology to ensure high food quality and efficient delivery. Its innovative approach includes the use of dark kitchens, which allow for streamlined operations and expanded menu options. Rebel Foods offers a range of food brands catering to different consumer dining occasions, including the well-known FAASOS brand, which focuses on retail food provision and home delivery services. By prioritizing ingredient sourcing and preparation standards, Rebel Foods aims to enhance the overall dining experience for food enthusiasts.

ThredUp Inc. is an online consignment and thrift store specializing in the resale of women's and children's apparel, shoes, and accessories. Founded in 2009 and headquartered in Oakland, California, ThredUp operates one of the largest resale platforms globally, promoting a sustainable shopping model by making it easy for consumers to buy and sell secondhand items. The company generates revenue through sales on its website and mobile app, as well as partnerships with retail-as-a-service providers. With a mission to encourage consumers to prioritize secondhand shopping, ThredUp aims to extend the life cycle of clothing and transform the fashion industry towards a more sustainable future.

ORIC Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing therapies to overcome resistance in cancer treatments. Founded in 2014 and based in South San Francisco, the company’s lead product candidate, ORIC-101, is a small molecule antagonist of the glucocorticoid receptor, which is associated with resistance to various cancer therapies in solid tumors. Its second candidate, ORIC-533, is an orally bioavailable small molecule inhibitor of CD73, targeting a critical component of the adenosine pathway linked to resistance against chemotherapy and immunotherapy. In addition to these products, ORIC is advancing multiple precision medicines aimed at addressing other mechanisms of cancer resistance. The company’s founders, Charles Sawyers and Scott Lowe, have extensive experience in identifying novel cancer targets that have led to innovative therapies.

Rebel Foods is a prominent operator of cloud kitchens that specializes in delivering food on demand through a variety of in-house brands. The company combines culinary expertise with advanced technology to ensure high food quality and efficient delivery. Its innovative approach includes the use of dark kitchens, which allow for streamlined operations and expanded menu options. Rebel Foods offers a range of food brands catering to different consumer dining occasions, including the well-known FAASOS brand, which focuses on retail food provision and home delivery services. By prioritizing ingredient sourcing and preparation standards, Rebel Foods aims to enhance the overall dining experience for food enthusiasts.

Foghorn Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing medicines that target genetically determined dependencies within the chromatin regulatory system. Utilizing its proprietary Gene Traffic Control platform, the company aims to understand and manipulate gene expression to develop innovative therapies for various diseases, particularly cancer. Foghorn is advancing several drug candidates, including FHD-286, an enzymatic inhibitor targeting BRG1 and BRM for acute myeloid leukemia and uveal melanoma, and FHD-609, a protein degrader aimed at treating synovial sarcoma. Additionally, the company has ongoing preclinical and discovery programs targeting non-small-cell lung cancer and other cancers associated with ARID1B mutations. Foghorn has established a collaboration with Merck Sharp & Dohme Corp. to create novel oncology therapeutics. Founded in 2015 and headquartered in Cambridge, Massachusetts, Foghorn Therapeutics is pioneering a new class of drug targets that could transform treatment approaches for patients with serious diseases.

Pearl is an AI-driven company focused on enhancing patient care within the dental field through its FDA-cleared technology. This advanced system is capable of identifying dental diseases in X-rays while recognizing various dental pathologies and natural anatomical features. By providing practitioners with robust data, Pearl's technology allows for improved patient interactions and better treatment options. Additionally, the company has developed a suite of solutions designed to automate tasks in dental laboratories, thereby increasing efficiency and precision in dental healthcare for clinicians, practice owners, labs, and insurers.

PAX Labs, Inc. is a manufacturer of premium vaporizers and accessories designed for loose-leaf and concentrates. The company's product lineup includes the PAX 3, PAX 2, and PAX Era, along with various accessories and a mobile application that enhances user experience. PAX Labs aims to simplify cannabis consumption by providing products that emphasize quality, transparency, and predictability. The company distributes its products through a network of retailers and distributors across the United States and internationally, as well as through its online platform. Founded in 2004 and headquartered in San Francisco, California, PAX Labs has established itself as an industry leader through innovation and thoughtful product design.

Dixie Brands is a leading producer of cannabis-infused products, established in 2010 following the legalization of medical marijuana in Colorado. The company specializes in crafting a variety of premium items, including sparkling beverages, edibles, sublingual tinctures, concentrates, topicals, and formulations that combine CBD and THC. Dixie Brands is committed to safety and quality, ensuring that all products are infused with CO2-extracted THC and undergo rigorous triple lab testing. With a mission to be a trusted source in the cannabis industry, Dixie Brands emphasizes innovation, research, education, and advocacy in its operations. The company has distinguished itself by being the first to obtain an Infused Products Retail Marijuana License, reflecting its leadership in the market for medical marijuana-infused products.

GOAT is a global platform headquartered in Los Angeles, California, specializing in the sale of authentic sneakers, apparel, and accessories from contemporary luxury brands. Founded in 2015 by Daishin Sugano and Eddy Lu, the company initially focused on building trust within the sneaker community but has since expanded its offerings to include a wide variety of styles from the past, present, and future. GOAT operates through both e-commerce and mobile applications, connecting over 20 million members across 164 countries. The platform features more than 350 brands and has established thirteen physical locations in the United States, Asia, and Europe, which include distribution and authentication centers. By leveraging innovative technology, GOAT provides a seamless shopping experience for buyers and sellers, verifying the authenticity of products and facilitating transactions in the sneaker market.

Rumble offers boxing-inspired fitness classes for a full-body strength and conditioning workouts crafted around specially designed water-filled, teardrop-style boxing bags. Rumble incorporates the best principles of the sweet science of boxing and strength training, all to help you develop that lean, strong, and confident fighter's physique. Rumble is HIIT (High-Intensity Interval Training), strength training, metabolic conditioning (METCON), and uppercut throwing cardio in one clean class.

Anaplan, Inc. offers a cloud-based connected planning platform that enables organizations to unify disparate data structures across various business functions, including finance, sales, supply chain, marketing, human resources, and operations. Founded in 2008 and headquartered in San Francisco, Anaplan provides its services through a subscription model, allowing users to access its platform over the Internet. The company focuses on enhancing decision-making and collaboration within organizations by delivering business planning and performance management solutions from a single hub. In addition to its core platform, Anaplan offers professional services, including consulting, implementation, training, and planning transformation advisory services. With operations in multiple countries and a network of expert partners, Anaplan supports large and fast-growing organizations in streamlining their planning processes and making informed decisions.

Bombas is an apparel brand founded in 2013 in New York, specializing in the manufacture of high-quality athletic socks for men, women, teens, and girls. The company also offers a range of other products, including underwear and t-shirts. Through its online platform, Bombas provides customers with comfortable, soft, and durable apparel at affordable prices. In addition to its focus on quality, the brand is committed to social responsibility, donating one item for every item sold to those in need.

GOAT is a global platform headquartered in Los Angeles, California, specializing in the sale of authentic sneakers, apparel, and accessories from contemporary luxury brands. Founded in 2015 by Daishin Sugano and Eddy Lu, the company initially focused on building trust within the sneaker community but has since expanded its offerings to include a wide variety of styles from the past, present, and future. GOAT operates through both e-commerce and mobile applications, connecting over 20 million members across 164 countries. The platform features more than 350 brands and has established thirteen physical locations in the United States, Asia, and Europe, which include distribution and authentication centers. By leveraging innovative technology, GOAT provides a seamless shopping experience for buyers and sellers, verifying the authenticity of products and facilitating transactions in the sneaker market.

Instacart is a prominent grocery delivery service operating in the United States and Canada, facilitating rapid deliveries of groceries and home essentials, often within an hour. The company partners with a variety of local and national grocers, including well-known brands such as Safeway, Whole Foods, and Costco, allowing customers to select from over 500,000 items and combine orders from multiple stores. Instacart employs a network of approximately 600,000 independent contractors who pick and deliver items directly to customers' homes. In addition to its delivery services, Instacart generates revenue by charging fees based on order value and by offering advertising opportunities primarily to consumer-packaged goods companies. With nearly 8 million monthly active users, Instacart has established itself as a leading platform in the grocery delivery market.

Lyft is a prominent transportation company that operates a mobile application designed to connect drivers with passengers seeking rides. Established in 2013, Lyft serves as the second-largest ride-sharing service provider in the United States and Canada, offering a range of ride options, including traditional private rides, shared rides, and luxury services. The app not only facilitates ride requests but also manages payments and allows users to schedule rides up to seven days in advance. In addition to its core ride-sharing services, Lyft has expanded into the bike and scooter-sharing markets, providing users with multimodal transportation solutions. The company's primary focus is on serving college, university, and corporate communities.